Paclitaxel, Cisplatin and Methotrexate Combination Chemotherapy is Active in the Treatment of Refractory Urothelial Malignancies

Purpose: We investigated the activity of combination chemotherapy consisting of paclitaxel, cisplatin and methotrexate in patients with advanced urothelial cancers. Materials and Methods: A total of 25 consecutive patients with metastatic refractory urothelial malignancies was treated with a combination of 200 mg./m.² paclitaxel, 30 mg./m.² methotrexate and 70 mg./m. sup 2 cisplatin in a pilot study. Results: There were no complete responses. Of 25 patients 10 (40 percent), including 3 of 7 with liver metastases, had a partial response. Hematological and nonhematological toxicity was tolerable. Conclusions: The combination chemotherapeutic regimen of paclitaxel, cisplatin and methotrexate is active in patients with advanced urothelial cancer and warrants further study.